ESMO

Addition of PARP Inhibitor to Maintenance Therapy May Improve Survival in Ovarian Cancer

September 28th 2019, 11:18pm

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Erleada May Extend Subsequent Progression in Men With Castration-Resistant Prostate Cancer

September 28th 2019, 6:43pm

Article

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

Latest News

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Utilizing AI in Prostate Cancer Care and Management

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation

View More Latest News